Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | CCR4 | P51679 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2451096 | 1.00 | CYP1A2 (0.34) | CYP1A2S1PR1LMNAMAOAMAOB | |
| SCHEMBL2482496 | 0.97 | LMNA (0.33) | CYP1A2S1PR1LMNAMAOAMAOB | |
| SCHEMBL2775359 | 0.97 | LMNA (0.33) | CYP1A2S1PR1LMNAMAOAMAOB | |
| SCHEMBL2455383 | 0.97 | LMNA (0.33) | CYP1A2S1PR1LMNAMAOAMAOB | |
| SCHEMBL2482503 | 0.97 | LMNA (0.33) | CYP1A2S1PR1LMNAMAOAMAOB | |
| SCHEMBL2452013 | 0.93 | ROCK1 (0.34) | LMNAMAOAMAOBROCK1CCR4 | |
| SCHEMBL2451992 | 0.93 | ROCK1 (0.34) | LMNAMAOAMAOBROCK1CCR4 | |
| SCHEMBL2776070 | 0.89 | CCR4 (0.38) | LMNAMAOAMAOBROCK1CCR4 | |
| SCHEMBL2779149 | 0.89 | CCR4 (0.38) | LMNAMAOAMAOBROCK1CCR4 | |
| SCHEMBL2779153 | 0.89 | CCR4 (0.38) | LMNAMAOAMAOBROCK1CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364088-B1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC INC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8546359-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130059821-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2013-03-07 | — | — | US | disclosed |
| US-8269043-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2364088-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010051030-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | S1PR1, S1PR3, S1PR4 | CYP1A2 4004/4885S1PR1 1/4885LMNA 3016/4885 |
| US-20130059821-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR3 | CYP1A2 4821/4885S1PR1 1/4885LMNA 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.